Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Bad
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Bad
|
New words:
aberrant, Adenocarcinoma, article, BioRxiv, blockade, Bulletin, closure, Codification, cold, colon, criteria, deal, discovered, disruption, Distinguishing, EITF, equivalent, exemption, fractional, headed, hot, immunologically, induced, infusion, maturation, Monday, mRNA, MTD, nearest, newly, Phosphorylation, private, promulgated, proper, radiotherapy, reappear, release, retroactively, rounded, similarly, software, Spliceosome, Splicing, stable, symbol, synergy, titled, transition, Tuesday, Wednesday
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view